Here's why a leading fund manager is excited by this ASX healthcare share

WAM thinks this stock is capable of producing good returns.

| More on:
Two happy pharmacists standing together in a pharmacy.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investment outfit Wilson Asset Management (WAM) is always on the hunt for undervalued growth shares. Which might be why ASX healthcare share Sigma Healthcare Ltd (ASX: SIG) is a pick inside one of WAM's listed investment companies (LICs).

A LIC invests in shares/assets that it believes can produce good returns for shareholders, and WAM Research Limited (ASX: WAX) has a deep research process to find such opportunities. It looks at factors like free cash flowreturn on equity (ROE), meeting management, and a company's overall quality.

On paper, Sigma may not sound like a rapidly growing business. It describes itself as a leading Australian full-line wholesale and distribution business to pharmacies. It has retail pharmacy brands, including Amcal and Discount Drug Stores, as well as an independent offering called PriceSave.

But there's one key reason why WAM likes the ASX healthcare shares so much.

Potential merger with Chemist Warehouse

Sigma is currently attempting to merge with Chemist Warehouse, the biggest pharmacy business in Australia.

Combining the two companies would lead to significant scale, adding revenue and cost synergies. A combined business would have the potential to generate much bigger profits than if the two companies stayed separate.

The Australian Competition and Consumer Commission (ACCC) is considering this proposed merger carefully because it could reduce competition in the pharmacy space.

The ACCC said it had concerns, including "the potential harm to pharmacies currently supplied by Sigma and the potential for Chemist Warehouse to access these pharmacies' data in ways that damage competition".

However, Sigma recently offered a number of court-enforceable undertakings to attempt to allay the ACCC's fears.

WAM noted that despite the ongoing regulatory process, the market appeared more confident that the proposed merger with Chemist Warehouse would be approved.

The investment team said the Chemist Warehouse management remained confident in its ability to expand in Australia and overseas.

If the merger does get the go-ahead, the WAM team is "excited at the prospect of owning one of the country's best retailers with a global store roll-out on the horizon".

What will the ASX healthcare share do to get the deal across the line?

Sigma's undertakings include not preventing or hindering franchisees who entered into their franchising arrangements before 1 January 2024 from terminating their franchise agreements with Sigma for a period of three years.

Next, it would place restrictions on the collection, use and disclosure of confidential data and information from Sigma's wholesale customers and customers for a period of three years.

Finally, Sigma would also remain a participating pharmaceutical wholesale under the Commonwealth Government's Community Service Obligation (CSO) arrangements for at least five years.

The ACCC is seeking feedback about these moves to address competition concerns, and it continues to investigate the impact of the proposed acquisition.

Sigma Healthcare share price snapshot

The company's stock has climbed a hefty 85% since the start of 2024, as shown in the chart below.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »